This report examines how artificial intelligence (AI) is reshaping the emerging drugs market by accelerating drug discovery, improving clinical development and supporting the development of novel therapies. It highlights AI applications across gene therapies, cell therapies, RNA-based therapeutics and precision medicine, along with their impact on research efficiency, development timelines and treatment innovation.
Report Includes
- Impact analysis of artificial intelligence (AI) on the market for emerging drug discovery and development
- Case studies for successful integration of AI technologies for enhanced clinical trials, accelerated drug discovery, and cost reduction
- Highlights of AI’s impact across the major geographic regions and end-user industries
- Review of disruptions caused by AI across key industry verticals and the impact on various stages of global supply chain
- Competitive landscape featuring strategic initiatives, market spendings and VC funding outlook
Table of Contents
Chapter 1 Key Use Cases for AI Adoption in Emerging Drugs- Overview
- Key Use Cases
- Case 1: AI-Driven Patient Pre-Screening and Recruitment
- Case 2: GenAI for De Novo Drug Design and Optimization
- Case 3: AI-Powered Predictive Toxicology and Safety Profiling
- Case 4: AI-Driven Drug Repurposing
- Adoption Trends at the Geography Level
- Adoption Trends in North America
- Adoption Trends in Europe
- Adoption Trends in Asia-Pacific
- Adoption Trends in the Rest of the World
- Impact of AI on Key Industry Verticals
- AI-Enabled Target Discovery and Validation
- AI-Driven Molecular Design and Optimization
- Predictive Clinical Development and Precision Medicine
- AI-Enhanced Drug Repurposing and Combination Therapy Discovery
- Impact of AI on Various Stages of the Supply Chain
- Key Spending by Companies on AI
- Abbreviations Used in the Report
Table 1: Key Spending by Companies on AI
Table 2: Abbreviations Used in This Report
